668 related articles for article (PubMed ID: 21796370)
1. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour.
Deiana S; Watanabe A; Yamasaki Y; Amada N; Arthur M; Fleming S; Woodcock H; Dorward P; Pigliacampo B; Close S; Platt B; Riedel G
Psychopharmacology (Berl); 2012 Feb; 219(3):859-73. PubMed ID: 21796370
[TBL] [Abstract][Full Text] [Related]
2. Development of a Rapid LC-MS/MS Method for the Quantification of Cannabidiol, Cannabidivarin, Δ
Piscitelli F; Pagano E; Lauritano A; Izzo AA; Di Marzo V
Anal Chem; 2017 Apr; 89(8):4749-4755. PubMed ID: 28343385
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC.
Hložek T; Uttl L; Kadeřábek L; Balíková M; Lhotková E; Horsley RR; Nováková P; Šíchová K; Štefková K; Tylš F; Kuchař M; Páleníček T
Eur Neuropsychopharmacol; 2017 Dec; 27(12):1223-1237. PubMed ID: 29129557
[TBL] [Abstract][Full Text] [Related]
4. Cannabis sativa: Much more beyond Δ
Alves P; Amaral C; Teixeira N; Correia-da-Silva G
Pharmacol Res; 2020 Jul; 157():104822. PubMed ID: 32335286
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Phytocannabinoids in Epilepsy Treatment: Novel Approaches and Recent Advances.
Farrelly AM; Vlachou S; Grintzalis K
Int J Environ Res Public Health; 2021 Apr; 18(8):. PubMed ID: 33920188
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.
Rock EM; Sticht MA; Duncan M; Stott C; Parker LA
Br J Pharmacol; 2013 Oct; 170(3):671-8. PubMed ID: 23902479
[TBL] [Abstract][Full Text] [Related]
7. Effect of Non-psychotropic Plant-derived Cannabinoids on Bladder Contractility: Focus on Cannabigerol.
Pagano E; Montanaro V; Di Girolamo A; Pistone A; Altieri V; Zjawiony JK; Izzo AA; Capasso R
Nat Prod Commun; 2015 Jun; 10(6):1009-12. PubMed ID: 26197538
[TBL] [Abstract][Full Text] [Related]
8. Quantification of cannabinoids and their free and glucuronide metabolites in whole blood by disposable pipette extraction and liquid chromatography-tandem mass spectrometry.
Scheidweiler KB; Newmeyer MN; Barnes AJ; Huestis MA
J Chromatogr A; 2016 Jul; 1453():34-42. PubMed ID: 27236483
[TBL] [Abstract][Full Text] [Related]
9. Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.
McPartland JM; Duncan M; Di Marzo V; Pertwee RG
Br J Pharmacol; 2015 Feb; 172(3):737-53. PubMed ID: 25257544
[TBL] [Abstract][Full Text] [Related]
10. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
De Petrocellis L; Ligresti A; Moriello AS; Allarà M; Bisogno T; Petrosino S; Stott CG; Di Marzo V
Br J Pharmacol; 2011 Aug; 163(7):1479-94. PubMed ID: 21175579
[TBL] [Abstract][Full Text] [Related]
11. The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination.
Robaina Cabrera CL; Keir-Rudman S; Horniman N; Clarkson N; Page C
Pulm Pharmacol Ther; 2021 Aug; 69():102047. PubMed ID: 34082108
[TBL] [Abstract][Full Text] [Related]
12. Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability.
O'Brien LD; Wills KL; Segsworth B; Dashney B; Rock EM; Limebeer CL; Parker LA
Pharmacol Biochem Behav; 2013 Jan; 103(3):597-602. PubMed ID: 23103902
[TBL] [Abstract][Full Text] [Related]
13. Terpenes and Cannabinoids Yields and Profile from Direct-Seeded and Transplanted CBD-
Zheljazkov VD; Noller JS; Maggi F; Dale R
J Agric Food Chem; 2022 Aug; 70(34):10417-10428. PubMed ID: 35436102
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders.
Fernández-Trapero M; Pérez-Díaz C; Espejo-Porras F; de Lago E; Fernández-Ruiz J
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32054131
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
[TBL] [Abstract][Full Text] [Related]
16. The structurally diverse phytocannabinoids cannabichromene, cannabigerol and cannabinol significantly inhibit amyloid β-evoked neurotoxicity and changes in cell morphology in PC12 cells.
Marsh DT; Sugiyama A; Imai Y; Kato R; Smid SD
Basic Clin Pharmacol Toxicol; 2024 Mar; 134(3):293-309. PubMed ID: 37697481
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of transdermal permeation of cannabinoids and their pharmacodynamic evaluation in rats.
Salau O; Bagde A; Kalvala A; Singh M
Int J Pharm; 2022 Aug; 624():122016. PubMed ID: 35863593
[TBL] [Abstract][Full Text] [Related]
18. Nonpsychotropic cannabinoids, abnormal cannabidiol and canabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure.
Szczesniak AM; Maor Y; Robertson H; Hung O; Kelly ME
J Ocul Pharmacol Ther; 2011 Oct; 27(5):427-35. PubMed ID: 21770780
[TBL] [Abstract][Full Text] [Related]
19. Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice.
Iannotti FA; Pagano E; Moriello AS; Alvino FG; Sorrentino NC; D'Orsi L; Gazzerro E; Capasso R; De Leonibus E; De Petrocellis L; Di Marzo V
Br J Pharmacol; 2019 May; 176(10):1568-1584. PubMed ID: 30074247
[TBL] [Abstract][Full Text] [Related]
20. The Origin and Biomedical Relevance of Cannabigerol.
Jastrząb A; Jarocka-Karpowicz I; Skrzydlewska E
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
